Ranking Profile - EyeGate Pharmaceuticals Inc

Introduction

Kiora Pharmaceuticals Inc (Kiora), formerly EyeGate Pharmaceuticals Inc, is a clinical-stage specialty pharmaceutical and drug delivery company that develops and commercializes products for treating diseases and disorders of the eye. The company's pipeline consists of three product candidates, including KIO-101, KIO-301, and KIO-201. Its lead product, KIO-301, is a potential vision-restoring small molecule that is designed to restore vision in patients with inherited and age-related degenerative retinal diseases. KIO-101 is a non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) that focuses on patients with Ocular Presentation of Rheumatoid Arthritis (OPRA). Its KIO-201 is a synthetic modified hyaluronic acid (HA) capable of coating the ocular surface and designed to resist degradation under conditions present in the eye. Kiora is headquartered in Salt lake city, Utah, the US.